bluebird bio Announces First Patient Transplanted in Phase 2/3 Starbeam ALD-102 Study for the Treatment of CCALD Read more about bluebird bio Announces First Patient Transplanted in Phase 2/3 Starbeam ALD-102 Study for the Treatment of CCALD
bluebird bio Joins the Russell 2000® Index Read more about bluebird bio Joins the Russell 2000® Index
Richard Morgan, Ph.D. Joins bluebird bio as Vice President of Immunotherapy Read more about Richard Morgan, Ph.D. Joins bluebird bio as Vice President of Immunotherapy
bluebird bio to Present at Morgan Stanley Global Healthcare Conference Read more about bluebird bio to Present at Morgan Stanley Global Healthcare Conference
bluebird bio Selected As A 2014 Technology Pioneer By The World Economic Forum Read more about bluebird bio Selected As A 2014 Technology Pioneer By The World Economic Forum
bluebird bio Reports Fiscal Second Quarter 2013 Financial Results Read more about bluebird bio Reports Fiscal Second Quarter 2013 Financial Results
bluebird bio to Present at Two Upcoming Conferences Read more about bluebird bio to Present at Two Upcoming Conferences
bluebird bio Announces Closing of Initial Public Offering and Exercise of Over-Allotment Option Read more about bluebird bio Announces Closing of Initial Public Offering and Exercise of Over-Allotment Option
bluebird bio Announces Pricing of Initial Public Offering Read more about bluebird bio Announces Pricing of Initial Public Offering
bluebird bio Announces Global Clinical Plans to Treat Adrenoleukodystrophy (ALD) Read more about bluebird bio Announces Global Clinical Plans to Treat Adrenoleukodystrophy (ALD)